Guilford Seeks To Triple Gliadel Market With First-Line Indication
Executive Summary
Approval of Guilford Pharmaceuticals' Gliadel Wafer for first-line treatment of metastatic brain cancer could triple use of the product, the company reported.
You may also be interested in...
Guilford Gliadel Glioma Trial Shows Consistent Modest Benefit – Cmte.
Guilford's Gliadel Wafer demonstrates a consistent, if modest, benefit in treatment of newly diagnosed malignant glioma, FDA's Oncologic Drugs Advisory Committee concluded
Guilford Gliadel Glioma Trial Shows Consistent Modest Benefit – Cmte.
Guilford's Gliadel Wafer demonstrates a consistent, if modest, benefit in treatment of newly diagnosed malignant glioma, FDA's Oncologic Drugs Advisory Committee concluded
Guilford Gliadel First-Line Use: Data Stratification To Be Considered By Cmte.
Guilford's Gliadel Wafer stratification of clinical results will be considered by FDA's Oncologic Drugs Advisory Committee in its review of the drug for first-line treatment of malignant glioma, originally scheduled for Sept. 11.